BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-850@pharmaconomics
DTSTAMP:20260707T015648Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:SLS Phase 3 — Galinpepimut-S (GPS)
DESCRIPTION:Phase 3 trial results for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) are due Jun 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1390478/000139047826000009/sls-202605128xkexhibit991.htm\n\nTrack it: https://pharmaconomics.com/e/850
URL:https://pharmaconomics.com/e/850
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:SLS catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR